EXEL

Exelixis, Inc. NASDAQ

Healthcare ·Biotechnology ·US · exelixis.com

$44.17

Mkt Cap $11.2B

52w Low $33.76 65.6% of range 52w High $49.62

50d MA $43.30 200d MA $41.68

P/E (TTM) 15.2x

EV/EBITDA 12.5x

P/B 5.5x

Debt/Equity 0.1x

ROE 36.2%

P/FCF 14.0x

RSI (14) —

ATR (14) —

Beta 0.42

50d MA $43.30

200d MA $41.68

Avg Volume 2.8M

About

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressi… Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 10, 2026	AMC	0.77	0.94	+22.1%	42.98	+1.1%	-0.1%	-0.7%	+2.2%	+2.6%	+3.5%	—
Nov 4, 2025	AMC	0.69	0.78	+13.9%	37.90	+5.5%	+6.5%	+7.7%	+7.7%	+9.3%	+13.4%	—
Jul 28, 2025	AMC	0.65	0.75	+15.4%	44.39	-13.8%	-16.8%	-17.0%	-18.4%	-16.1%	-17.1%	—
May 13, 2025	AMC	0.36	0.62	+73.1%	36.95	+10.0%	+20.8%	+25.2%	+22.9%	+20.9%	+20.1%	—
Feb 11, 2025	AMC	0.51	0.55	+7.8%	32.81	+1.2%	-0.0%	+5.1%	+6.7%	+4.2%	+6.9%	—
Oct 29, 2024	AMC	0.35	0.40	+14.3%	28.73	+9.3%	+12.9%	+15.6%	+18.8%	+19.4%	+21.0%	—
Aug 6, 2024	AMC	0.30	0.77	+156.7%	23.45	+6.6%	+13.1%	+15.9%	+15.0%	+14.8%	+13.9%	—
Apr 30, 2024	AMC	0.28	0.17	-39.3%	23.46	-7.8%	-6.5%	-5.7%	-6.6%	-6.6%	-5.6%	—
Feb 6, 2024	AMC	0.21	0.27	+28.6%	21.83	-3.4%	-7.6%	-7.6%	-7.4%	-6.6%	-7.3%	—
Nov 1, 2023	AMC	0.10	0.10	+0.0%	21.02	-2.6%	-4.2%	-0.1%	-0.9%	+0.4%	-1.3%	—
Aug 1, 2023	AMC	0.16	0.25	+56.2%	19.63	+1.9%	+3.6%	+5.8%	+3.3%	+3.2%	+4.4%	—
May 9, 2023	AMC	0.15	0.12	-20.0%	19.23	+0.0%	+0.8%	+0.6%	-0.3%	+1.4%	-0.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 20	Barclays	Maintains	Equal Weight → Equal Weight	—	$44.89	$44.99	+0.2%	-2.9%	+2.2%	+4.4%	+2.6%	+0.1%
Mar 2	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$44.06	$42.00	-4.7%	-6.9%	-7.5%	-5.4%	-6.3%	-5.7%
Feb 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.94	$42.83	-0.3%	-0.6%	+2.3%	+2.7%	+3.6%	+2.8%
Feb 11	Stifel	Maintains	Hold → Hold	—	$42.98	$43.46	+1.1%	-0.1%	-0.7%	+2.2%	+2.6%	+3.5%
Feb 11	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$42.98	$43.46	+1.1%	-0.1%	-0.7%	+2.2%	+2.6%	+3.5%
Feb 11	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$42.98	$43.46	+1.1%	-0.1%	-0.7%	+2.2%	+2.6%	+3.5%
Feb 4	Barclays	Maintains	Equal Weight → Equal Weight	—	$42.59	$42.79	+0.5%	+0.1%	-0.5%	+3.1%	+3.2%	+0.9%
Feb 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.81	$42.51	-0.7%	-0.5%	-0.4%	-1.0%	+2.5%	+2.7%
Feb 2	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$41.36	$42.01	+1.6%	+3.5%	+3.0%	+3.1%	+2.4%	+6.1%
Jan 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.61	$43.80	+0.4%	+0.3%	-2.2%	-3.0%	-5.2%	-1.8%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$46.19	$45.37	-1.8%	-4.4%	-4.7%	-4.6%	-4.6%	-2.1%
Jan 8	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$46.19	$45.37	-1.8%	-4.4%	-4.7%	-4.6%	-4.6%	-2.1%
Nov 6	UBS	Maintains	Neutral → Neutral	—	$40.37	$40.05	-0.8%	+1.1%	+1.1%	+2.6%	+6.5%	+8.0%
Nov 5	Barclays	Maintains	Equal Weight → Equal Weight	—	$37.90	$40.00	+5.5%	+6.5%	+7.7%	+7.7%	+9.3%	+13.4%
Nov 5	TD Cowen	Maintains	Buy → Buy	—	$37.90	$40.00	+5.5%	+6.5%	+7.7%	+7.7%	+9.3%	+13.4%
Nov 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.90	$40.00	+5.5%	+6.5%	+7.7%	+7.7%	+9.3%	+13.4%
Nov 5	Morgan Stanley	Maintains	Overweight → Overweight	—	$37.90	$40.00	+5.5%	+6.5%	+7.7%	+7.7%	+9.3%	+13.4%
Nov 3	Guggenheim	Downgrade	Buy → Neutral	—	$38.67	$37.55	-2.9%	-1.6%	-2.0%	+4.4%	+5.5%	+5.5%
Oct 21	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$34.54	$35.05	+1.5%	+4.6%	+4.5%	+10.2%	+12.1%	+15.8%
Oct 21	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$34.54	$35.05	+1.5%	+4.6%	+4.5%	+10.2%	+12.1%	+15.8%
Oct 21	Leerink Partners	Upgrade	Market Perform → Outperform	—	$34.54	$35.05	+1.5%	+4.6%	+4.5%	+10.2%	+12.1%	+15.8%
Oct 21	Morgan Stanley	Maintains	Overweight → Overweight	—	$34.54	$35.05	+1.5%	+4.6%	+4.5%	+10.2%	+12.1%	+15.8%
Sep 17	Morgan Stanley	Maintains	Overweight → Overweight	—	$39.14	$39.66	+1.3%	+3.3%	+3.3%	+2.5%	+1.1%	+1.7%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.41	$37.52	+0.3%	+1.4%	+2.9%	+2.8%	+2.4%	+0.9%
Jul 30	UBS	Maintains	Neutral → Neutral	—	$36.94	$37.14	+0.5%	-0.2%	-1.9%	+0.9%	-0.4%	+1.4%
Jul 29	Guggenheim	Maintains	Buy → Buy	—	$44.39	$38.26	-13.8%	-16.8%	-17.0%	-18.4%	-16.1%	-17.1%
Jul 29	Truist	Maintains	Buy → Buy	—	$44.39	$38.26	-13.8%	-16.8%	-17.0%	-18.4%	-16.1%	-17.1%
Jul 29	Stifel	Maintains	Hold → Hold	—	$44.39	$38.26	-13.8%	-16.8%	-17.0%	-18.4%	-16.1%	-17.1%
Jul 29	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$44.39	$38.26	-13.8%	-16.8%	-17.0%	-18.4%	-16.1%	-17.1%
Jul 29	Morgan Stanley	Maintains	Overweight → Overweight	—	$44.39	$38.26	-13.8%	-16.8%	-17.0%	-18.4%	-16.1%	-17.1%
Jul 29	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$44.39	$38.26	-13.8%	-16.8%	-17.0%	-18.4%	-16.1%	-17.1%
Jul 22	Morgan Stanley	Maintains	Overweight → Overweight	—	$44.26	$44.29	+0.1%	+0.5%	+2.6%	+1.2%	+3.0%	+0.3%
Jul 15	Truist	Maintains	Buy → Buy	—	$45.58	$45.59	+0.0%	-3.3%	-1.7%	-1.6%	-2.4%	-2.9%
Jul 11	UBS	Maintains	Neutral → Neutral	—	$45.17	$45.00	-0.4%	-0.7%	+0.9%	-2.5%	-0.8%	-0.7%
Jul 10	Barclays	Maintains	Equal Weight → Equal Weight	—	$44.07	$44.24	+0.4%	+2.5%	+1.8%	+3.4%	-0.0%	+1.7%
Jul 8	RBC Capital	Downgrade	Outperform → Sector Perform	—	$44.16	$43.82	-0.8%	-1.5%	-0.2%	+2.3%	+1.6%	+3.2%
Jun 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.67	$43.87	+0.5%	+0.9%	-0.1%	+1.4%	+5.7%	+1.1%
Jun 24	Stephens & Co.	Upgrade	Equal Weight → Overweight	—	$43.37	$44.55	+2.7%	+5.4%	+0.4%	-0.6%	+0.7%	+1.6%
Jun 23	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$40.37	$49.43	+22.4%	+7.4%	+13.3%	+7.8%	+6.7%	+8.2%
Jun 23	Truist	Maintains	Buy → Buy	—	$40.37	$49.43	+22.4%	+7.4%	+13.3%	+7.8%	+6.7%	+8.2%
Jun 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$41.43	$41.59	+0.4%	+0.8%	+0.4%	+0.8%	-0.2%	-1.7%
Jun 5	BofA Securities	Maintains	Neutral → Neutral	—	$42.22	$42.14	-0.2%	+0.4%	+1.9%	+1.7%	+0.7%	-1.9%
May 15	Citigroup	Maintains	Buy → Buy	—	$44.65	$44.55	-0.2%	+3.6%	+1.7%	+0.1%	-0.6%	-2.1%
May 14	RBC Capital	Maintains	Outperform → Outperform	—	$36.95	$40.65	+10.0%	+20.8%	+25.2%	+22.9%	+20.9%	+20.1%
May 14	Stifel	Maintains	Hold → Hold	—	$36.95	$40.65	+10.0%	+20.8%	+25.2%	+22.9%	+20.9%	+20.1%
May 14	Morgan Stanley	Maintains	Overweight → Overweight	—	$36.95	$40.65	+10.0%	+20.8%	+25.2%	+22.9%	+20.9%	+20.1%
Apr 17	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$36.15	$36.03	-0.3%	+0.1%	-1.5%	+0.9%	+1.7%	+2.9%
Mar 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.01	$37.25	+0.6%	-0.5%	-0.8%	-0.2%	-1.7%	+0.1%
Mar 13	RBC Capital	Maintains	Outperform → Outperform	—	$37.20	$37.25	+0.1%	-1.1%	-1.5%	-0.5%	-2.3%	-0.4%
Feb 24	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$36.85	$36.39	-1.2%	+0.8%	+0.2%	+1.8%	+2.2%	+5.0%

Recent Filings

8-K

Exelixis Inc -- 8-K Filing

Exelixis appointed Hefti as Senior Vice President and General Counsel, strengthening its legal and executive leadership team.

Feb 10

Data updated apr 25, 2026 8:09am · Source: massive.com